SCHEMBL8737774

SCHEMBL8737774

CC(=O)Nc1nc(C)c(-c2csc(Nc3cc(C(N)=O)ccc3OC(C)C)n2)s1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 1/20 0.59
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
POLB P06746 1/20 0.58
PIK3CG P48736 2/20 0.56
MITF O75030 1/20 0.56
RAB9A P51151 1/20 0.56
ALDH1A1 P00352 5/20 0.55
MAPT P10636 5/20 0.55
KDM4E B2RXH2 4/20 0.55
GAA P10253 3/20 0.55
HTT P42858 3/20 0.55
LMNA P02545 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
USP2 O75604 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
GFER P55789 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6114360 0.99 MMP9 (0.58) MMP9MEN1KMT2APOLBPIK3CG
SCHEMBL8738025 0.90 MMP9 (0.73) MMP9MEN1KMT2APOLBALDH1A1
SCHEMBL8738335 0.90 MAPT (0.55) MMP9MEN1KMT2APOLBPIK3CG
Bromide SCHEMBL6114358 0.89 MMP9 (0.72) MMP9MEN1KMT2APOLBMITF
SCHEMBL8739511 0.89 MMP9 (0.61) MMP9MEN1KMT2APOLBPIK3CG
SCHEMBL8738028 0.89 MEN1 (0.56) MEN1KMT2ARAB9AALDH1A1MAPT
SCHEMBL6114193 0.89 MEN1 (0.58) MEN1KMT2APOLBRAB9AALDH1A1
SCHEMBL8738338 0.89 TRPV4 (0.52) MEN1KMT2APOLBALDH1A1MAPT
Bromide SCHEMBL6113988 0.88 MEN1 (0.56) MEN1KMT2APOLBRAB9AALDH1A1
Bromide SCHEMBL6113998 0.88 MEN1 (0.57) MEN1KMT2APOLBRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA N.V. (BE) 2012-05-24 US disclosed
WO-2012068209-A2 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION JANSSEN PHARMACEUTICA NV (BE) 2012-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129842-A1 BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION MMP1, MMP9, MMP2 MMP9 2/4885MEN1 2298/4885KMT2A 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.